teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 36 Projects Releases Packages Wiki Activity Actions 1

extract: 2025-12-23-jama-cardiology-select-hospitalization-analysis

Browse source 
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents 2026-03-16 11:41:01 +00:00
parent d3bc723eff
commit e56d469776
2 changed files with 20 additions and 1 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

6
domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md
View file

@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
- Nature Medicine: additive benefits with SGLT2 inhibitors
- First GLP-1 to receive FDA indication for CKD in T2D patients
### Additional Evidence (extend)
*Source: [[2025-12-23-jama-cardiology-select-hospitalization-analysis]] | Added: 2026-03-16*
SELECT trial exploratory analysis (N=17,604, median 41.8 months) shows semaglutide reduces ALL-CAUSE hospitalizations by 10% (18.3 vs 20.4 per 100 patient-years, P<.001) and total hospital days by 11% (157.2 vs 176.2 days per 100 patient-years, P=.01). Critically, benefits extended beyond cardiovascular causes to total hospitalization burden, suggesting systemic effects across multiple organ systems.
---
Relevant Notes:

15
inbox/archive/2025-12-23-jama-cardiology-select-hospitalization-analysis.md
View file

@ -7,9 +7,13 @@ date: 2025-12-23
domain: health
secondary_domains: [internet-finance]
format: paper
status: unprocessed
status: enrichment
priority: high
tags: [glp-1, semaglutide, hospitalization, cardiovascular, SELECT-trial, cost-offset]
processed_by: vida
processed_date: 2026-03-16
enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md"]
extraction_model: "anthropic/claude-sonnet-4.5"
---
## Content
@ -36,3 +40,12 @@ Median age 61.0 years; 27.7% female; median BMI 32.1.
PRIMARY CONNECTION: [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]
WHY ARCHIVED: All-cause hospitalization reduction is the most economically relevant outcome for risk-bearing payers and the strongest evidence that GLP-1s could be cost-saving under capitation
EXTRACTION HINT: Focus on the all-cause hospitalization signal (not just CV) — this is what makes GLP-1s relevant to VBC economics beyond cardiology
## Key Facts
- SELECT trial: N=17,604 patients with obesity and established CVD, median follow-up 41.8 months
- Median age 61.0 years, 27.7% female, median BMI 32.1
- Total hospitalizations: 18.3 vs 20.4 per 100 patient-years (mean ratio 0.90, P<.001)
- Hospitalizations for serious adverse events: 15.2 vs 17.1 per 100 patient-years (mean ratio 0.89, P<.001)
- Days hospitalized: 157.2 vs 176.2 per 100 patient-years (rate ratio 0.89, P=.01)
- Published in JAMA Cardiology as prespecified exploratory analysis